ABSTRACT
OBJECTIVE: Bergenin (BGN) is a C-glycoside of 4-O-methylgallic acid with anti-inflammatory, antioxidant, and tissue-repairing abilities. Here, we probed the roles and mechanisms of BGN in ischemic stroke-mediated cerebral injury. METHODS: The middle cerebral artery occlusion (MCAO) model was established in mice, which were injected intraperitoneally with varying concentrations of BGN (10, 20, and 40 mg/kg). The modified neurological severity score (mNSS) and the water maze experiment were adopted to evaluate mice's neural functions (movement and memory). The brain edema was assessed by the dry and wet method. TdT-mediated dUTP nick end labeling (TUNEL)-labeled apoptotic neurons and Iba1-labeled microglia in the cortex were measured by immunohistochemistry (IHC). Quantitative reverse transcription-PCR and ELISA were implemented to determine the expression of inflammatory cytokines (TNFα, IL-1ß, and IL-6), neurotrophic factors (BDNF and VEGF), and oxidative stress factors (SOD and MDA) in brain tissues. The profiles of Sirt1, FOXO3a, Nrf2, NF-κB, and STAT6 in brain tissues were checked by western blot. RESULTS: BGN significantly improved MCAO mice's cognitive, learning, and motor functions, reduced brain edema, hampered the production of inflammatory factors and oxidative stress mediators, and suppressed neuronal apoptosis. Additionally, BGN dampened the expression of proinflammatory cytokines and upregulated neurotrophic factors and oxidative stress factors in ischemic brain tissues of MCAO mice. Meanwhile, BGN reduced the expression of inflammatory cytokines and oxidative stressors in oxygen-glucose deprivation/reoxygenation-induced BV2 microglia. Further mechanistic studies revealed that BGN concentration dependently elevated the profiles of Sirt1, FOXO3a, STAT6, and Nrf2, and abated the NF-κB phosphorylation. CONCLUSION: BGN protects against ischemic stroke in mice by boosting the Sirt1/FOXO3a pathway, suggesting its potential as a therapeutic agent for ischemic stroke.
Subject(s)
Benzopyrans , Brain Edema , Ischemic Stroke , Neuroprotective Agents , Animals , Anti-Inflammatory Agents/pharmacology , Antioxidants/pharmacology , Benzopyrans/pharmacology , Brain Edema/drug therapy , Cytokines/metabolism , Disease Models, Animal , Forkhead Box Protein O3/drug effects , Forkhead Box Protein O3/metabolism , Infarction, Middle Cerebral Artery/complications , Infarction, Middle Cerebral Artery/drug therapy , Infarction, Middle Cerebral Artery/metabolism , Ischemic Stroke/drug therapy , Mice , NF-E2-Related Factor 2/metabolism , NF-kappa B/drug effects , NF-kappa B/metabolism , Nerve Growth Factors/metabolism , Neuroprotective Agents/pharmacology , Neuroprotective Agents/therapeutic use , Oxidative Stress/drug effects , Sirtuin 1/drug effects , Sirtuin 1/metabolismABSTRACT
Previous evidence has shown that the long intergenic non-protein coding RNA 858 (LINC00858) is an oncogene in non-small cell lung cancers. However, the role LINC00858 plays in gastric cancer (GC) is not clear. To illustrate the role LINC00858 plays in GC, the LINC00858 expression in GC and normal tissues was firstly detected. Then, the viability, proliferation and migration of GC BGC823 and MGC803 cells were assessed following LINC00858 knockdown by si-LINC00858 transfection. The results showed that LINC00858 had a high level of expressions in GC tissues as demonstrated by both online data and qRT-PCR assay. Also, the knockdown of LINC00858 reduced the proliferation and migration of BGC823 and MGC803 cells in vitro. Taken together, our data indicate that LINC00858 plays an oncogenic role in GC cells and might act as a potential therapeutic target for GC.
Subject(s)
RNA, Long Noncoding/genetics , Stomach Neoplasms , Cell Line, Tumor , Cell Movement/genetics , Cell Proliferation/genetics , Gene Expression Regulation, Neoplastic , Humans , Stomach Neoplasms/genetics , Up-RegulationABSTRACT
OBJECTIVE: To evaluate the efficacy of the proprioceptive sensibility reflexotherapy by tendon acupuncture needling at trigger points for patients with proprioceptive disorder of cervical vertigo. METHODS: Seventy-nine patients with proprioceptive disorder of cervical vertigo were randomly assigned into a treatment group (42 cases) and a control group (37 cases). Patients in the treatment group received the proprioceptive sensibility reflexotherapy with tendon acupuncture at trigger points in the neck. And those in the control group were given traditional traction, massage and intermediate frequency electro therapy. All the treatment was given for 2 courses, once a day and 10 days as a course. The cervical vertigo symptom and function, the joint position error (JPE) and stability index (ST) before and after treatment were observed in the two groups and the effects were evaluated. RESULTS: The cervical vertigo symptom and function were improved, JPE and ST decreased after treatment in the two groups (all P<0.05), with better results in the treatment group (all P<0.05). CONCLUSIONS: The proprioceptive sensibility reflexotherapy with tendon acupuncture at trigger points is effective for proprioceptive disorder of cervical vertigo.
